Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT) announces today that it has successfully raised € 14.3 m in gross proceeds through a private placement of new shares with institutional investors, other qualifying investors who subscribed for at least € 50,000 per investor in various jurisdictions and the members of the Board of Management (the “Private Placement”). Pursuant to the Private Placement AMT will issue 8,435,294 new ordinary shares with a nominal value of € 0.04 each for an offer price of € 1.70 per share.
The net proceeds of the Private Placement will increase AMT's financial flexibility and will be used to fund Glybera® through its regulatory and commercial development and to continue the development of the hemophilia and other pipeline programs.
The payment and delivery of the new shares is expected to take place on October 11, 2010, at which date the new shares are also expected to be admitted to listing on NYSE Euronext in Amsterdam.
Immediately after the closing of the Private Placement, AMT’s issued and outstanding share capital will amount to 23,504,022 ordinary shares.
No comments:
Post a Comment